Activation of the urotensin-II receptor by anti-COVID-19 drug remdesivir induces cardiomyocyte dysfunction
F.-Y. Wei, A. Inoue, A. Ogawa, S. Ohira, T. Ikuta, Y. Kato, S. Yanagida, Y. Ishii, Y. Kanda, M. Nishida
This study identifies remdesivir as a selective agonist of the urotensin-II receptor, linking its cardiotoxicity to receptor activation and genetic variants.
bioRxiv · Aug 8, 2022 · PreprintPharmacology & Toxicology